Previous 10 | Next 10 |
2024-06-16 07:19:35 ET Summary Sanofi's shares have not fully recovered since announcing a business strategy change in October 2023, focusing on R&D investments and on separating its consumer healthcare business unit. The company's immunology business, led by Dupixent and othe...
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study PR Newswire Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to pat...
2024-06-14 17:53:40 ET Summary Vanguard Health Care ETF focuses on investing in successful healthcare companies with $20 billion in assets and a low expense ratio of 0.10%. Top holdings include Eli Lilly, UnitedHealth Group, and Johnson & Johnson, offering potential for growth...
2024-06-14 15:55:36 ET More on Bristol-Myers Squibb Company , Gilead Sciences, etc. Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Bristol-Myers...
2024-06-14 11:23:25 ET More on Johnson & Johnson Johnson & Johnson: Market Will Regret The Overreaction Cancer victims seek court order to block J&J’s bankruptcy bid J&J in $700M settlement with states over marketing of talc products Jo...
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma PR Newswire 24-month overall survival rate of 67 percent achieved with TALVEY ® 0.8 mg/kg biweekly dosing in the Phase 1/2 Monum...
2024-06-13 18:32:48 ET Summary Boston Scientific Corporation is outperforming its peers in the med-tech sector with exceptional growth driven by key products like Farapulse and Watchman. Farapulse and Watchman are well-appreciated drivers with significant upside, but other contrib...
2024-06-13 15:02:59 ET More on Xencor Seeking Alpha’s Quant Rating on Xencor Historical earnings data for Xencor Financial information for Xencor Read the full article on Seeking Alpha For further details see: Xencor to regain rights from J...
2024-06-13 14:03:52 ET Summary Contineum Therapeutics, Inc. PIPE-791 is being developed for the treatment of neuroinflammatory disorders like idiopathic pulmonary fibrosis and Progressive Multiple Sclerosis. The global idiopathic pulmonary fibrosis market size is projected to reac...
2024-06-12 17:45:04 ET Summary Kenvue (KVUE) was created as the result of a spinoff from Johnson & Johnson and encompasses the consumer side of the business. KVUE manages a wide array of products within each segment, but sales volume remains vulnerable to consumer spending. ...
News, Short Squeeze, Breakout and More Instantly...
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Canada NewsWire Phase 3 PAPILLON study sh...
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study PR Newswire CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S....
2024-07-01 06:50:00 ET Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments. Three Motley Fool contributors think they've found magnificent stocks retir...